Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14576985 | 0.92 | PTK2 (0.49) | JAK3PTK2FLT4LCK | |
| SCHEMBL12478681 | 0.91 | PTK2 (0.51) | JAK3PTK2FLT4LCK | |
| SCHEMBL12478010 | 0.90 | PTK2 (0.53) | JAK3PTK2FLT4LCK | |
| SCHEMBL15506605 | 0.86 | JAK3 (0.46) | JAK3PTK2LCKULK1 | |
| SCHEMBL14576468 | 0.81 | PTK2 (0.49) | JAK3PTK2FLT4LCK | |
| SCHEMBL14576849 | 0.81 | PTK2 (0.50) | JAK3GSK3AGSK3BPTK2LCK | |
| SCHEMBL15524695 | 0.81 | JAK3 (0.51) | JAK3GSK3AGSK3BPTK2LCK | |
| SCHEMBL12478815 | 0.81 | ALK (0.55) | JAK3PTK2AURKA | |
| SCHEMBL12478971 | 0.80 | PTK2 (0.49) | JAK3PTK2LCK | |
| SCHEMBL15514106 | 0.80 | FLT4 (0.50) | JAK3PTK2FLT4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9238644-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-19 | — | — | US | disclosed |
| US-20160009686-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| EP-2885291-A1 | VEGFR3 INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2015-06-24 | — | — | EP | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140073620-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-13 | — | — | US | disclosed |
| WO-2014026243-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 26/4885GSK3A 446/4885GSK3B 283/4885 |
| US-20160009686-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 20/4885GSK3A 420/4885GSK3B 289/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 26/4885GSK3A 419/4885GSK3B 294/4885 |
| US-20140073620-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 20/4885GSK3A 420/4885GSK3B 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.